Vyjayanthi Atluri, MD
Geriatric Medicine · Burr Ridge, ILNPI 1023067311
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $584 and has fallen 67.8% since, to $188 in 2025.
Across 77 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$329
- Acadia Pharmaceuticals Inc$314
- Pfizer$301
- Astellas Pharma US Inc$152
- Eisai Inc.$136
- Novartis$92
- plus $485 from 15 others
What the payments were for
- Food & beverage$1,808100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 10 | $329 |
| Acadia Pharmaceuticals Inc | 12 | $314 |
| Pfizer | 15 | $301 |
| Astellas Pharma US Inc | 8 | $152 |
| Eisai Inc. | 2 | $136 |
| Novartis | 5 | $92 |
| Mylan Specialty L.p. | 4 | $74 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Alpha Cognition USA, Inc. | 1 | $43 |
| Urovant Sciences Inc | 2 | $40 |
| Lundbeck LLC | 2 | $34 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| CMP Pharma, Inc. | 1 | $24 |
| Melinta Therapeutics, LLC | 1 | $20 |
| Amgen | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| AstraZeneca | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,808 in reported general payments places this provider in the 85th percentile of 147 geriatric medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 739 | $262,763 |
| XareltoRivaroxaban | 141 | $64,063 |
| MyrbetriqMirabegron | 163 | $60,704 |
| JanuviaSitagliptin Phosphate | 47 | $42,444 |
| ZenpepLipase/Protease/Amylase | 23 | $27,429 |
| JardianceEmpagliflozin | 63 | $22,520 |
| RybelsusSemaglutide | 13 | $15,553 |
| Memantine Hcl | 330 | $10,708 |
| TradjentaLinagliptin | 23 | $10,547 |
| Potassium Chloride | 348 | $10,376 |
| Midodrine Hcl | 146 | $9,627 |
| Levothyroxine Sodium | 741 | $9,509 |
| Mirtazapine | 295 | $9,058 |
| EntrestoSacubitril/Valsartan | 17 | $8,897 |
| Atorvastatin Calcium | 638 | $8,457 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $301 | $262,763739 claims |
| Johnson & JohnsonXarelto | $329 | $64,063141 claims |
| Astellas Pharma US IncMyrbetriq | $152 | $60,704163 claims |
| Novo NordiskRybelsus | $16 | $15,55313 claims |
| NovartisEntresto | $92 | $8,89717 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $44 | $7,44254 claims |
| AstraZenecaBrilinta | $14 | $5,74034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 147 geriatric medicine providers in Illinois.
Other geriatric medicine in Burr Ridge
- Shahla NyaemeBurr Ridge$3K
- Rahmawati SihBurr Ridge$2K
- Michael LimArlington Heights$29K
- Hima AtluriDecatur$21K
- Carlos Mella-PicelChicago$9K
- Rekha SharmaHazel Crest$8K
- Beata StykaPalos Heights$6K
- Azeem AhsanCrest Hill$6K
- Adeela CheemaChicago$5K
- Alex SanchezElgin$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.